.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
Novartis
Cerilliant
Fish and Richardson
Medtronic
McKesson
Accenture
Moodys
Colorcon

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,001,861

« Back to Dashboard

Which drugs does patent 6,001,861 protect, and when does it expire?


Patent 6,001,861 protects MIRAPEX and is included in one NDA. There have been three Paragraph IV challenges on Mirapex.

This patent has thirty-nine patent family members in twenty-five countries.

Summary for Patent: 6,001,861

Title: Use of pramipexole in the treatment of restless legs syndrome
Abstract:The present invention provides the use of pramipexole in the treatment of restless legs syndrome.
Inventor(s): Oertel; Wolfgang H. (Ranschenberg, DE), Meier; Dieter (Weisbaden, DE), Gomez-Mancilla; Baltazar (Portage, MI), Montplaisir; Jacques (Montreal, CA)
Assignee: Pharmacia & Upjohn Company (Kalamzoo, MI)
Application Number:09/008,212
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimMIRAPEXpramipexole dihydrochlorideTABLET;ORAL020667-001Jul 1, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
Boehringer IngelheimMIRAPEXpramipexole dihydrochlorideTABLET;ORAL020667-002Jul 1, 1997ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
Boehringer IngelheimMIRAPEXpramipexole dihydrochlorideTABLET;ORAL020667-006Feb 12, 1998ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
Boehringer IngelheimMIRAPEXpramipexole dihydrochlorideTABLET;ORAL020667-007Jul 30, 2007ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
Boehringer IngelheimMIRAPEXpramipexole dihydrochlorideTABLET;ORAL020667-003Jul 1, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
Boehringer IngelheimMIRAPEXpramipexole dihydrochlorideTABLET;ORAL020667-005Jul 1, 1997ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,001,861

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,194,445 Use of pramipexole in the treatment of restless legs syndrome► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,001,861

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Africa9800420► Subscribe
World Intellectual Property Organization (WIPO)9831362► Subscribe
Slovakia284264► Subscribe
Slovakia92099► Subscribe
Slovenia0989850► Subscribe
Slovenia20060► Subscribe
Russian Federation2192252► Subscribe
Portugal989850► Subscribe
Romania120757► Subscribe
Poland190898► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Merck
Accenture
McKinsey
Citi
Julphar
QuintilesIMS
Deloitte
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot